Clinical trials: Adverse Drug Reactions
Artificial Intelligent, Cardiotoxicity
Smart Home Care of Cloud Base ECG on the Cardiotoxicity Prevention on the Cancer Patients.
Thoracic malignancy is the most commonly diagnosed cancer worldwide.1,2 The incidence of thoracic malignancy has decreased in North America, but not in Asia, where it continues to show an increasing trend.
- Conditions
- Artificial Intelligent, Cardiotoxicity, Cardiac Monitor, Cancer Treatment
- Trial name
- AI (NCT04885088)
- Testing
- Wisdom bracelet
- Volunteers
- 400 people
- Sponsor
- Ju-Chi Liu
Non Small Cell Lung Cancer, Cardiotoxicity
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
- Trial name
- NCT07761910
- Testing
- PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Cardiotoxicity, Acute Myeloid Leukemia in Children
Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia
Prevention and early detection of chemotherapy-induced cardiotoxicity in children with bone tumors and Acute Myeloid Leukemia by giving capoten
- Conditions
- Cardiotoxicity, Acute Myeloid Leukemia in Children, Bone Tumor
- Trial name
- NCT03389724
- Testing
- Capoten®
- Where
- Egypt
- Volunteers
- 245 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Adverse Drug Reaction (ADR)
The INTEGRATE Study: Integrated Pharmacogenetics, TDM and Active Pharmacovigilance as Innovative Tools for the Optimisation and Appropriateness of Drug Therapy
The primary goal of this observational study is to evaluate the feasibility of implementing a multidisciplinary approach based on pharmacogenetics, TDM (Therapeutic Drug Monitoring) and MedReview into the clinical practice in…
- Trial name
- INTEGRATE (NCT06822959)
- Testing
- Pharmacogenetics, TDM and MedReview
- Where
- 2 sites in Italy
- Volunteers
- 450 people
- Sponsor
- Direzione centrale salute, politiche sociali e disabilità
Arthritis, Cancer
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events (irAEs) from rhumatologic, endocrinologic, cardiac or other system origin.
- Conditions
- Arthritis, Cancer, Cardiac Disease, Endocrine System Diseases
- Trial name
- CHIMeRA (NCT03492242)
- Testing
- Immune checkpoint inhibitor
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Kidney Impairment
Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy
This study is to investigate blood and urine kidney injury markers (especially Uromodulin) in pediatric cancer patients treated with nephrotoxic chemotherapy.
- Trial name
- Kid-MaCareOnco (NCT04308642)
- Testing
- blood test for renal biomarkers, urine test for renal biomarkers
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- University Hospital, Basel, Switzerland
Perioperative Complication, Hypersensitivity
Defining ENDOtypes in Perioperative Hypersensitivity by Extensive Cellular and Molecular PHENotyping (ENDOPHEN)
Perioperative Acute Hypersensitivity (PAH) is a systemic reaction that occurs rapidly following injection of a drug during anesthesia.The HSA-PA reaction must occur within a maximum of one hour after the induction of anesthesia…
- Trial name
- ENDOPHEN (NCT04006106)
- Where
- 7 sites in France
- Volunteers
- 103 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adverse Drug Event
Adverse Drug Events at Emergency Department
Emergency departments (EDs) are a crucial element of the health care systems at interface between hospital and communities. The goals of the ED are to make an initial diagnosis and deliver urgent and critical care 24 hour per day…
- Trial name
- ADEsED (NCT03442010)
- Testing
- Detection of adverse drug events
- Where
- France
- Volunteers
- 13,453 people
- Sponsor
- University Hospital, Montpellier
Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.
- Trial name
- NCT00024427
- Testing
- fluorouracil, gemcitabine hydrochloride, triacetyluridine
- Where
- 29 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Wellstat Therapeutics
Chronic Pain, Hypertension
Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction
The purpose of this study (PASSION study) is to monitor symptoms of chronic pain before and after 2 weeks of a standard drug commonly used to treat elevated blood pressure compared with 2 weeks of placebo (crossover design) so…
- Conditions
- Chronic Pain, Hypertension, Diuretics Drug Reactions, SCS
- Trial name
- PASSION (NCT04676399)
- Testing
- Hydrochlorothiazide 12.5mg
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Kansas Medical Center
Adverse Drug Related Events
Development of a Screening Strategy for Community-based Adverse Drug Related Events in the Emergency Department
Adverse Drug Related Events (ADREs) are a leading cause of Emergency Department (ED) visits in Canada. However emergency physicians recognize only half of all ADREs in patients presenting to the ED, missing opportunities to…
- Trial name
- NCT00727610
- Where
- 2 sites in Canada
- Volunteers
- 1,588 people
- Sponsor
- University of British Columbia
Drug Toxicity
Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects
To Evaluate the safety and tolerability after KD101 single oral dosing in healthy male subjects To Evaluate the pharmacokinetic property after KD101 single oral dosing in healthy male subjects To Evaluate the effect of food on…
- Trial name
- NCT01979380
- Testing
- KD101
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Cardiotoxicity, Thoracic Radiotherapy
Optimizing Radiation Dose and Utilizing Wearable Devices to Reduce Arrhythmia Risk in Patients Undergoing Thoracic Radiotherapy: A Prospective Cohort Study
This prospective observational cohort study aims to assess the risk of radiation-induced cardiotoxicity in patients undergoing thoracic radiotherapy by integrating real-time arrhythmia monitoring using wearable cardiac…
- Conditions
- Cardiotoxicity, Thoracic Radiotherapy, Wearable Electronic Devices, Thoracic Neoplasms
- Trial name
- NCT06897189
- Where
- South Korea
- Volunteers
- 111 people
- Sponsor
- Yonsei University
Neuroendocrine Tumors, Carcinoid Syndrome
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
The purpose of the protocol is to to assess subject's overall satisfaction regarding control of diarrhea. The study aims to supplement results obtained through clinical trials with data obtained from a population of patients…
- Trial name
- SYMNET (NCT01234168)
- Where
- 57 sites in Czechia, France and 6 more
- Volunteers
- 340 people
- Sponsor
- Ipsen
Neuroendocrine Tumors, Carcinoid Syndrome
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
The NET-PACS trial is a Prospective Assessment of patients with neuroendocrine tumors and current or prior history of Carcinoid Syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat…
- Conditions
- Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea
- Trial name
- NET-PACS (NCT04713202)
- Testing
- Telotristat ethyl, Peptide Receptor Radionuclide Therapy
- Where
- United States
- Sponsor
- Chandrikha Chandrasekhara
Cancer
Detection of Chemotherapy Induced Cardiotoxicity
To identify patients that are at risk of heart damage after receiving chemotherapy (adriamycin).
- Trial name
- NCT00636844
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- George Washington University
Cardiomyopathy, Cardiac Failure
Cardiac Assessment of Patients With Hip Implants
PRIMARY OBJECTIVE To establish the effect of metal ion release from metal hip implants on cardiac function STUDY OUTCOME MEASURES To assess the effect of metal ions from hip implants on cardiac function as measured by Cardiac…
- Trial name
- NCT02331264
- Testing
- Exposure to metal debris
- Where
- 2 sites in United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Royal National Orthopaedic Hospital NHS Trust
Drug-Related Side Effects and Adverse Reaction, Digoxin Overdose
Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults
The intervention consists of introducing computerized alerts into the electronic medical record of the CSAPG (MIRA software), which are triggered when a physician prescribes digoxin at a dose higher than the recommended amount…
- Trial name
- Aldigo (NCT07008144)
- Testing
- Digoxin alarm
- Where
- 2 sites in Spain
- Volunteers
- 5,954 people
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Solid Tumor, Capecitabine
Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Capecitabine is one of the most active agents in the treatment of many kinds of solid tumors. However, variability in toxicity and response remains a major problem for patients receiving capecitabine.
- Conditions
- Solid Tumor, Capecitabine, Drug-Related Side Effects and Adverse Reactions, Pharmacogenetics
- Trial name
- NCT03258099
- Testing
- detection of genotype
- Where
- 7 sites in China
- Volunteers
- 2,200 people
- Sponsor
- Cui Yimin
Solid Cancer, Gastric (Cardia, Body) Cancer
Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form.
- Conditions
- Solid Cancer, Gastric (Cardia, Body) Cancer, Esophageal Cancer, Colorectal Cancer (CRC)
- Trial name
- ESCAPE (NCT07114627)
- Testing
- Blood sampling for pharmacokinetics
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- Erasmus Medical Center